April 20, 2023
BSE Limited
Surveillance Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400001
Scrip Code: 543245
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,
Sub: Clarification regarding increase in volumes- your e-mail dated 20 ${ }^{\text {th }}$ April 2023
Ref. No.: L/SURV/ONL/PV/AA/ 2023-2024 / 30
This is in reference to your e-mail dated $20^{\text {th }}$ April 2023 seeking clarification on increase in volume of the shares on Stock Exchanges.

We wish to submit that as on date, there is no information which requires disclosure by the Company in terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"). Further, since the shares of the Company are freely traded on the stock exchanges, the Company is unable to comment on the increase in the volume of shares of the Company on the stock exchanges.

The Company has always taken its obligations under the Listing Regulations seriously and will continue to do so, and thus, as and when matters arise that require disclosure, the Company will comply with its obligations under the Listing Regulations and make appropriate disclosures.

Please take the same on record.
Yours truly,
For Gland Pharma Limited

P Sampath Kumar<br>Company Secretary and Compliance Officer

